Published in J Acquir Immune Defic Syndr on December 15, 2008
Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis (2009) 2.24
The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol (2009) 1.55
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS (2012) 1.34
Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther (2011) 1.28
The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One (2012) 1.27
d-Dimer and CRP levels are elevated prior to antiretroviral treatment in patients who develop IRIS. Clin Immunol (2010) 1.26
Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther (2011) 1.14
Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses (2012) 1.13
HIV-Associated Venous Thromboembolism. Mediterr J Hematol Infect Dis (2011) 1.11
Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. Int J Vasc Med (2011) 0.95
Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels. AIDS (2009) 0.91
Management of HIV infection in treatment-naive patients: a review of the most current recommendations. Am J Health Syst Pharm (2011) 0.91
Relationship of body composition, metabolic status, antiretroviral use, and HIV disease factors to endothelial dysfunction in HIV-infected subjects. AIDS Res Hum Retroviruses (2010) 0.89
Biomarkers and HIV-associated cardiovascular disease. Curr Opin HIV AIDS (2010) 0.87
Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with disease-associated factors and mortality. Am J Ophthalmol (2011) 0.84
Assessment of biomarkers of cardiovascular risk among HIV type 1-infected adolescents: role of soluble vascular cell adhesion molecule as an early indicator of endothelial inflammation. AIDS Res Hum Retroviruses (2012) 0.83
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia. PLoS One (2015) 0.81
Carotid intima media thickness, inflammatory markers, and endothelial activation markers in HIV Patients with lipoatrophy increased at 48 weeks regardless of use of rosiglitazone or placebo. AIDS Res Hum Retroviruses (2010) 0.81
Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. Epidemiology (2014) 0.81
Changes in Inflammation, Oxidative Stress, Mitochondrial DNA Content after Rosiglitazone in HIV Lipoatrophy. J AIDS Clin Res (2012) 0.76
LL-37 concentrations and the relationship to vitamin D, immune status, and inflammation in HIV-infected children and young adults. AIDS Res Hum Retroviruses (2014) 0.76
Recent key advances in human immunodeficiency virus medicine and implications for China. AIDS Res Ther (2010) 0.76
Bone effects of rosiglitazone in HIV-infected patients with lipoatrophy. HIV Clin Trials (2012) 0.75
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One (2011) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Abdominal adiposity and coronary heart disease in women. JAMA (1998) 6.21
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med (2004) 5.86
Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) (1984) 5.79
Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med (1996) 5.20
Atherosclerosis is an inflammatory disease. Am Heart J (1999) 5.12
Life without white fat: a transgenic mouse. Genes Dev (1998) 5.08
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS (2003) 4.43
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation (1997) 4.41
Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology (2003) 4.28
Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res (2004) 3.93
Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem (2000) 3.90
Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis (2000) 3.81
Association between myeloperoxidase levels and risk of coronary artery disease. JAMA (2001) 3.74
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest (2000) 3.41
Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr (2002) 3.33
Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis (1999) 3.21
Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS (2005) 3.07
Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS (2006) 2.98
Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation (2004) 2.79
Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet (2002) 2.50
Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart (1997) 2.50
A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS (2006) 2.35
The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol (1993) 2.13
Cardio- and cerebrovascular events in HIV-infected persons. AIDS (2004) 1.98
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol (1995) 1.74
Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation (2004) 1.68
Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis (2003) 1.62
Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS (2004) 1.61
Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol (2001) 1.58
Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem (2001) 1.47
Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis (2003) 1.42
Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patients. Coron Artery Dis (2000) 1.38
Metabolic syndrome and subclinical atherosclerosis in patients infected with HIV. Clin Infect Dis (2007) 1.37
Does HIV infection independently increase the incidence of lung cancer? Clin Infect Dis (2005) 1.32
Acute T-cell activation is detectable in unstable angina. Circulation (1997) 1.19
Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res (2006) 1.17
Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med (2005) 1.15
Interleukin 6 is associated with subclinical atherosclerosis: a link with soluble intercellular adhesion molecule 1. J Hypertens (2006) 1.14
Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation (2006) 1.14
Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart (2003) 1.06
Immune system activation follows inflammation in unstable angina: pathogenetic implications. J Am Coll Cardiol (1998) 1.04
Endothelial function and inflammation in coronary artery disease. Heart (2005) 1.03
Carotid atherosclerosis is associated with inflammation, malnutrition and intercellular adhesion molecule-1 in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant (2004) 1.02
Body-composition measurements as predictors of glucose and insulin abnormalities in HIV-positive men. Am J Clin Nutr (2002) 1.02
Serum interleukin-6 correlates with endothelial dysfunction in healthy men independently of insulin sensitivity. Diabetes Care (2007) 0.97
Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am J Cardiol (2006) 0.96
HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine (2006) 0.94
Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens (2004) 0.91
Glucose tolerance and the risk of cardiovascular disease: the Zutphen Study. J Clin Epidemiol (1992) 0.90
What a cardiologist needs to know about patients with human immunodeficiency virus infection. Circulation (2005) 0.87
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy. J Infect Dis (2010) 2.37
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis (2011) 2.35
Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis (2009) 2.24
Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis (2014) 1.86
Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care (2010) 1.86
Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther (2010) 1.83
Interleukin-10 controls the onset of irreversible septic shock. Infect Immun (2002) 1.76
Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS (2014) 1.46
How low is too low? Use of cluster analysis to define low levels of mercaptopurine metabolites. Pediatr Blood Cancer (2006) 1.45
Increased carotid intima media thickness and cardiac biomarkers in HIV infected children. AIDS (2007) 1.40
Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit. Pediatr Crit Care Med (2009) 1.39
Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis (2013) 1.36
Medical Geneticists' duty to warn at-risk relatives for genetic disease. Am J Med Genet A (2003) 1.36
Metabolic complications of HIV therapy in children. AIDS (2004) 1.28
Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther (2011) 1.28
Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr (2015) 1.25
Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther (2011) 1.23
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis (2013) 1.23
Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS (2013) 1.23
Fractures after antiretroviral initiation. AIDS (2012) 1.21
Fatty Acid ethyl esters: quantitative biomarkers for maternal alcohol consumption. J Pediatr (2005) 1.17
Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther (2011) 1.14
HIV-1 is not a major driver of increased plasma IL-6 levels in chronic HIV-1 disease. J Acquir Immune Defic Syndr (2012) 1.12
Increased incidence of nonaccidental head trauma in infants associated with the economic recession. J Neurosurg Pediatr (2011) 1.10
Metabolic complications and treatment of perinatally HIV-infected children and adolescents. J Int AIDS Soc (2013) 1.09
Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children. Atherosclerosis (2010) 1.08
Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome. Shock (2005) 1.08
Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr (2013) 1.05
Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. J Acquir Immune Defic Syndr (2015) 1.05
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS (2015) 1.05
Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection. Antivir Ther (2008) 1.05
Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. AIDS (2012) 1.03
Risk factors for vitamin D deficiency and relationship with cardiac biomarkers, inflammation and immune restoration in HIV-infected youth. Antivir Ther (2012) 1.03
Ethanol inhibits L1 cell adhesion molecule activation of mitogen-activated protein kinases. J Neurochem (2006) 1.03
Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIV-infected individuals. J Acquir Immune Defic Syndr (2012) 1.03
Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2007) 1.01
Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr Infect Dis J (2010) 0.99
Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.99
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. J Antimicrob Chemother (2009) 0.99
Evaluation of prolonged aPTT values in the pediatric population. Clin Pediatr (Phila) (2006) 0.98
Urolithiasis with topiramate in nonambulatory children and young adults. Pediatr Neurol (2009) 0.97
Diagnosis of pediatric urolithiasis: role of ultrasound and computerized tomography. J Urol (2005) 0.96
Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J (2003) 0.96
Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Ann Intern Med (2015) 0.95
A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS (2012) 0.94
Elevated D-dimer is independently associated with endothelial dysfunction: a cross-sectional study in HIV-infected adults on antiretroviral therapy. Antivir Ther (2012) 0.94
High prevalence of overweight and obesity in females with phenylketonuria. Mol Genet Metab (2012) 0.93
Ethanol inhibits L1 cell adhesion molecule tyrosine phosphorylation and dephosphorylation and activation of pp60(src). J Neurochem (2009) 0.93
Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success. J Infect Dis (2011) 0.93
European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS (2011) 0.93
Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. AIDS (2016) 0.92
Evaluation of right ventricular fibrosis in adult congenital heart disease using gadolinium-enhanced magnetic resonance imaging: initial experience in patients with right ventricular loading conditions. Congenit Heart Dis (2006) 0.92
Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. Int J Cardiol (2013) 0.92
C-reactive protein predicts 96-week carotid intima media thickness progression in HIV-infected adults naive to antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.91
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study. Antivir Ther (2013) 0.91
Serogroup 19 pneumococci containing both mef and erm macrolide resistance determinants in an American city. Pediatr Infect Dis J (2006) 0.91
The choking game: physician perspectives. Pediatrics (2009) 0.90
Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection. AIDS (2016) 0.90
Do breastfeeding intentions of pregnant inner-city teens and adult women differ? Breastfeed Med (2010) 0.89
Omega-3 fatty acids do not improve endothelial function in virologically suppressed HIV-infected men: a randomized placebo-controlled trial. AIDS Res Hum Retroviruses (2011) 0.89
High proportion of false-positive Clostridium difficile enzyme immunoassays for toxin A and B in pediatric patients. Infect Control Hosp Epidemiol (2011) 0.89
Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr (2004) 0.88
Osteopenia and osteoporosis in patients with HIV: a review of current concepts. Curr Infect Dis Rep (2006) 0.88
Statins to improve cardiovascular outcomes in treated HIV infection. Curr Opin Infect Dis (2016) 0.87
Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study. AIDS (2014) 0.87
Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens. AIDS (2010) 0.87
Persistent elevation of serum interleukin-6 in intraabdominal sepsis identifies those with prolonged length of stay. J Pediatr Surg (2004) 0.86
Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS (2014) 0.86
An open-label pilot study of St. John's wort in juvenile depression. J Am Acad Child Adolesc Psychiatry (2003) 0.86
Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS (2013) 0.85
Effect of topiramate on seizures and respiratory dysrhythmia in Rett syndrome. J Child Neurol (2004) 0.85
Delay in diagnosis of Williams syndrome. Clin Pediatr (Phila) (2002) 0.85
A case of endocarditis caused by Lactococcus garvieae and suggested methods for identification. J Clin Microbiol (2013) 0.85
Statins Blunt HAART-Induced CD4 T-Cell Gains but Have No Long-Term Effect on Virologic Response to HAART. J Int Assoc Physicians AIDS Care (Chic) (2007) 0.84
Overuse injuries in high school athletes. Clin Pediatr (Phila) (2010) 0.84
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. J Acquir Immune Defic Syndr (2014) 0.84
A 26-week open-label study of quetiapine in children with conduct disorder. J Child Adolesc Psychopharmacol (2007) 0.84
Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry (2006) 0.83
Autonomic testing in functional gastrointestinal disorders: implications of reproducible gastrointestinal complaints during tilt table testing. Gastroenterol Res Pract (2009) 0.83
Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol (2004) 0.83